Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
J Egypt Natl Canc Inst ; 34(1): 43, 2022 Oct 17.
Article En | MEDLINE | ID: mdl-36245068

BACKGROUND: EGFR mutation has not been extensively studied in thyroid cancer. This study was conducted to study spectrum of EGFR mutation in thyroid cancer in Kashmiri population for possible therapeutic purpose. METHODS: It was 2 years prospective cross-sectional study conducted at a tertiary care center in which histologically confirmed, untreated thyroid cancers were included. These specimens were subjected to EGFR mutation analysis by AS-PCR method. RESULTS: There were a total 60 patients with preponderance of females [44(73%) vs 16(27%)]. Most were in the age group of less than 45 years (75%). Most of these patients were non-smokers [50(83.3%) vs 10 (17.3%)]. Papillary thyroid carcinoma (PTC) was the commonest type 48(80%), rest was follicular type (FTC) 12(20%). Well-differentiated carcinoma (WDC) was common than poorly differentiated (PDC) [41(68.4%) vs 19 (31.6%)]. Lymph node metastasis and vascular invasion were present in 32 (53.4%) and 17 (28.4%) respectively. Thirty-two (53.3%) patients were having 15 bp deletion in exon 19 of EGFR. These deletions were common in PTC than FTC, 29(60.5%) vs 3(25%) which was statistically significant (p = 0.04, CI = 0.2). The total mutational rate of T790M in EGFR tyrosine kinase domain (exon 20) was found to be only 8.4% (5 of 60). Only 4 (8.3%) of these mutations were detected in PTC and rest in FTC (1 of 12). Twenty-six (43.3%) of exon 21 were positive for L858R mutation in EGFR tyrosine kinase domain. Married persons and PDC were significant predictors of L858R mutation in EGFR tyrosine kinase domain in thyroid cancer as this was statistically significant in them with p = 0.04, 0.03 respectively. CONCLUSION: In our population, PTC is common in females with half of population harboring EGFR mutation and it is statistically significant in poorly differentiated carcinoma and in married individuals. It implies that EGFR may be used in thyroid cancer as a possible therapeutic agent in our set of population.


Lung Neoplasms , Thyroid Neoplasms , Cross-Sectional Studies , ErbB Receptors/genetics , Female , Humans , Lung Neoplasms/genetics , Middle Aged , Mutation , Prospective Studies , Protein Kinase Inhibitors/therapeutic use , Tertiary Care Centers , Thyroid Cancer, Papillary/epidemiology , Thyroid Cancer, Papillary/genetics , Thyroid Neoplasms/epidemiology , Thyroid Neoplasms/genetics
2.
Int J Biol Macromol ; 183: 1495-1504, 2021 Jul 31.
Article En | MEDLINE | ID: mdl-34029580

Guar gum is a neutral, non-ionic polysaccharide that has been extensively utilized in the food industry as a stabilizer, excipients, and emulsifier agent. An oxidized derivative of this edible guar gum was prepared and used as a complexing agent for iron to obtain a polysaccharide-bound iron (II) complex. The degree of oxidation varies between 30.12 and 60.63% with a corresponding aldehyde content (0.59-1.79 mmol/g) and carboxyl contents (0.49-1.62 mmol/g), which were determined by the titrimetry method. Sophisticated spectroscopic techniques characterized all the products. The natural polymer-based hydrophilic and hydrophobic formulations as coating were used for achieving the sustained or prolonged release from the complex tablets. Release studies of the tablets were carried out in different mediums of varying pH. The total iron available from the tablets was compared with that obtained from ferrous fumarate prepared under similar conditions, and the results were found to be comparable. Release results demonstrate the pH-sensitive behaviour of the guar gum-based delivery system towards the controlled release of iron. Antianemic effect of new functionalized guar gum iron complexes was investigated on male albino rats. The complexes may exhibit the potential to recover the hematological index of the albino rats with some positive effects on improving rat's growth with iron deficiency anaemia.


Anemia/drug therapy , Galactans/chemistry , Iron/chemistry , Mannans/chemistry , Plant Gums/chemistry , Anemia, Iron-Deficiency/drug therapy , Animals , Hydrogen-Ion Concentration , Hydrophobic and Hydrophilic Interactions , Male , Rats , Solubility , Tablets/chemistry , Tablets/therapeutic use
3.
Int J Biol Macromol ; 153: 1147-1156, 2020 Jun 15.
Article En | MEDLINE | ID: mdl-31760005

Folic acid a synthetic form of folate, is the oxidized form of folate which acts as a coenzyme in one carbon transfer reactions required in the biosynthesis of DNA and RNA and its deficiency could be related to diseases such as neural tube defects, Alzheimer's disease, pregnancy complications and cancer. Inulin is a polydisperse polysaccharide comprising mostly of fructosyl fructose units. An oxidized derivative of this inulin was prepared and used as a complexing agent for folic acid to obtain a polysaccharide bound folic acid conjugate. The aldehyde content and degree of oxidation of the oxidized inulin were determined by acid-base titrations. All the products were characterized by sophisticated spectroscopic and thermal methods of analysis. Release studies of folic acid from conjugates were carried out in different pH media and the results demonstrate the pH-sensitive behavior of the inulin-based delivery system towards the controlled release of folic acid.


Drug Carriers/chemistry , Drug Liberation , Folic Acid/chemistry , Inulin/chemistry , Aldehydes/chemistry , Amination , Molecular Weight , Oxidation-Reduction
...